Get the Stockscreener App
251.64
1.05%
-2.67
After Hours:
250.65
-0.99
-0.39%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $251.64, with a volume of 6.87M.
It is down -1.05% in the last 24 hours and up +15.58% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$254.31
Open:
$255
24h Volume:
6.87M
Relative Volume:
0.99
Market Cap:
$444.60B
Revenue:
$62.82B
Net Income/Loss:
$3.60B
P/E Ratio:
124.12
EPS:
2.0274
Net Cash Flow:
$19.98B
1W Performance:
+7.19%
1M Performance:
+15.58%
6M Performance:
+9.53%
1Y Performance:
+35.57%
1-Day Range:
$250.10
$255.50
1-Week Range:
$232.85
$255.99
52-Week Range:
$184.38
$255.99
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
251.64 | 447.62B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,199.43 | 1.08T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
253.97 | 613.02B | 96.36B | 21.04B | 17.80B | 8.6488 |
MRK
Merck Co Inc
|
128.50 | 317.77B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
156.72 | 296.54B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-30-26 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie (ABBV) Shares Dip After Six-Day Surge Amid $10.9B Acquisi - GuruFocus
AbbVie shares fell after six-session winning streak - MSN
Bristol, Merck, AbbVie face House committee probe over China trials - Seeking Alpha
What Sparked the $43B Jump in AbbVie's Market Cap in the Past Week? - TradingView
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity - Benzinga
Merck, AbbVie probed by US lawmakers over China clinical trials: report - Yahoo! Finance Canada
US lawmakers probe Merck and AbbVie China clinical trials - grafa.com
Why is AbbVie stock slipping today? By Investing.com - Investing.com Canada
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Merck, AbbVie investigated over China military hospital drug trials - Yahoo Finance
US House committee opens investigation into Merck, AbbVie China drug trials - marketscreener.com
Nxera reaches fourth R&D milestone under AbbVie accord - The Pharma Letter
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases - marketscreener.com
Nxera Pharma Co LtdNxera Pharma To Receive Us$10 Million Milestone Payment From Abbvie Under Collaboration Targeting Neurological Diseases - TradingView
Big Pharma Has a Case of Merger Mania - The Motley Fool
AbbVie Climbs to 52-Week High: Is the Pharma Giant Still Worth Buying? - NAI500
AbbVie (ABBV) Reports Positive Results for Epkinly in Lymphoma T - GuruFocus
AbbVie (ABBV) Reports Positive Phase 3 Trial Results for DLBCL T - GuruFocus
Juvederm Users Say AbbVie Hid Risks Of Filler - Law360
Is AbbVie (ABBV) One of the 10 Best July Dividend Stocks to Buy? - Insider Monkey
AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - marketscreener.com
AbbVie lymphoma trial cuts progression risk 60% in Phase 3 test - Stock Titan
AbbVie Stock Rockets 17% With 5-Day Winning Streak - Yahoo Finance
AbbVie (ABBV) Stock After 1-Year 41% Rally And Apogee Deal Valuation Check - Yahoo Finance Singapore
What's Going On With AbbVie Stock Monday?AbbVie (NYSE:ABBV) - Benzinga
AbbVie (ABBV) Wins Backing For Two RINVOQ Skin Disease Uses In Europe - Yahoo Finance
AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy? - Yahoo Finance
AbbVie (ABBV) Moves 4.2% Higher: Will This Strength Last? - Yahoo Finance
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $298 - Moomoo
$100M AbbVie payment backs REGENXBIO (RGNX) Phase IIb/III eye gene therapy - Stock Titan
ABBV Gains Traction as CHMP Recommends Upadacitinib for Alopecia Areata - GuruFocus
AbbVie Stock Surges 17%, With A 5-Day Winning Spree - Trefis
AbbVie Receives Positive CHMP Opinion for Upadacitinib for the Treatment of Adults and Adolescents with Severe Alopecia Areata - Investing News Network
AbbVie Receives Positive CHMP Opinion for Upadacitinib for the Treatment of Adults and Adolescents with Non-segmental Vitiligo - Investing News Network
AbbVie gets positive EU opinion for vitiligo treatment By Investing.com - Investing.com Canada
AbbVie’s upadacitinib receives positive EU opinion for alopecia By Investing.com - Investing.com Canada
AbbVie Inc.(NYSE: ABBV) added to Russell 1000 Value Benchmark - marketscreener.com
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata - Yahoo Finance
AbbVie’s RINVOQ moves closer to Europe’s first vitiligo pill - Stock Titan
ABBV Stock Quote Price and Forecast - CNN
AbbVie stock run lifts pricing on $10.9 billion Apogee deal to six times cost - TechStock²
AbbVie Inc.(NYSE: ABBV) added to Russell Top 200 Value Benchmark - marketscreener.com
Skyrizi Just Hit $4.5 Billion in a Single Quarter, AbbVie’s Humira Problem Is Solved - TIKR.com
AbbVie (ABBV) Wins Health Canada Approval for Boey - Insider Monkey
AbbVie (NYSE:ABBV) jumps $18 billion Friday, beats Apogee as Skyrizi FDA decision comes Monday - TechStock²
AbbVie (ABBV) to Acquire Apogee Therapeutics - Insider Monkey
SCHULHOFF & CO INC's AbbVie Inc(ABBV) Holding History - GuruFocus
Enterprise value to revenue forward of AbbVie, Inc. CDR (CAD Hedged) – TSX:ABBV - TradingView
Key facts: AbbVie Q2 Jul 31; FDA Approves Skyrizi for 6+ & Ped PsA - TradingView
AbbVie (ABBV) Gains FDA Approval for Skyrizi in Children with Ps - GuruFocus
ABBV Gains FDA Approval for Skyrizi in Pediatric Psoriasis Treat - GuruFocus
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):